Kailera CTO files initial ownership statement

Kailera Therapeutics, Inc. (KLRA) reported that Nicholson Nur, who serves as Chief Technology Officer, has filed an initial statement of beneficial ownership on Form 3.

Rhea-AI Filing Summary

Kailera Therapeutics, Inc. (KLRA) reported that Nicholson Nur, who serves as Chief Technology Officer, has filed an initial statement of beneficial ownership on Form 3. The filing lists no transactions or current holdings and notes an attached Exhibit 24 granting a Power of Attorney.

Key Terms

Form 3, beneficial ownership, Power of Attorney

3 terms

Form 3 regulatory

"has filed an initial statement of beneficial ownership on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"filed an initial statement of beneficial ownership on Form 3"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Power of Attorney regulatory

"remarks: "Exhibit 24 - Power of Attorney""

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the KLRA Form 3 filed for Nicholson Nur report?

It reports that Nicholson Nur, Chief Technology Officer of Kailera Therapeutics, Inc. (KLRA), has filed an initial statement of beneficial ownership. The Form 3 shows no reported transactions or holdings as of the filing and references an Exhibit 24 Power of Attorney.

What is Nicholson Nur’s role at Kailera Therapeutics (KLRA)?

Nicholson Nur is identified as an officer of Kailera Therapeutics, Inc., holding the title of Chief Technology Officer in the Form 3 filing.

Does the KLRA Form 3 disclose any insider trades by Nicholson Nur?

No. The Form 3 shows no transactions by Nicholson Nur. All transaction-related counts, including buy, sell, exercise, and gift transactions, are reported as zero.

Does Nicholson Nur report any current share holdings in KLRA on this Form 3?

No. The filing indicates no reported holdings, with zero holding entries and no derivative positions listed in the derivative summary for Nicholson Nur.

What is the Exhibit 24 mentioned in the KLRA Form 3?

The remarks section notes “Exhibit 24 - Power of Attorney”, indicating that a Power of Attorney document is attached to the filing, authorizing another party to act on Nicholson Nur’s behalf for certain filing-related matters.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 07:23 PM Accepted by SEC EDGAR 09/09/2026 - 07:23 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Nicholson Nur

(Last) (First) (Middle)

C/O KAILERA THERAPEUTICS, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/31/2026

3. Issuer Name and Ticker or Trading Symbol
Kailera Therapeutics, Inc. [ KLRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ John Mei, Attorney-in-fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)